

## **Suggested reading for Hematology (8/07)**

### **Sickle cell anemia**

Steinberg MH. Management of sickle cell disease. NEJM. 1999 340:1021-1030.

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004 Feb 26;350(9):886-95.

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005 Apr 6;293(13):1653-62. Review.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995 May 18;332(20):1317-22.

A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995 Jul 27;333(4):206-13.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51.

Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000 Jun 22;342(25):1855-65.

### **Polycythemia. Vera and essential thrombocytosis**

Schafer, AI, Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006. 107:4214-4222.

Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290.

James C. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005.

Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.

Ruggeri M, Finazzi G, Tosi A et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772-777.

Fruchtman SM, Pettit RM, Gilbert HS, Fidler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res. 2005;29:481-491.

### **Erythropoietin**

Gabrilove J., et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. *J Clin Oncol.* 2001;19(11):2875-82.

### **Bone marrow failure**

Moyo, V.M., Mukhina, G.L., Garrett, E.S., Brodsky, R.A. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. *British Journal of Haematology.* *Br J Haematol*, 126(1):133-8, 2004.

Brodsky, R.A., Jones, R.J. Aplastic anaemia. *Lancet*, 365:1647-1656, 2005

Brodsky, R.A., Sensenbrenner, L.L., Smith, B.D., Dorr, D., Seaman, P.J., Lee, S.M., Karp, J.E., Brodsky, I., Jones, R.J. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. *Annals of Internal Medicine*, 135:477-483, 2001.

Brodsky, R.A. Paroxysmal Nocturnal Hemoglobinuria. *In* *Hematology: Basic Principles and Practice*, Fourth Edition. (Hoffman, R., Ed.). Elsevier Science, Philadelphia, PA. 26: 419-427, 2005.

Young NS, Brown KE. Parvovirus B19. *New England Journal of Medicine*, 350:586-597

Sieff, C.A., Nisbet-Brown, E., Nathan, D.G. Congenital bone marrow failure syndromes. *British Journal of Haematology* 2000; 111:30-42.

Hillmen, M.B., Young, N.S., Schubert, J., **Brodsky, R.A.**, Socie, G., Muus, P., Roth, A., Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., Schrezenmeier, H., Fu, C., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, R.P., Luzzatto, L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. *New England Journal of Medicine*, 2006 Sep 21;355(12):1233-43.

### **Coagulation**

A. Srivastava. Dose and response in haemophilia - optimization of factor replacement therapy. *British Journal of Haematology.* 2004, 127:12-25.

Dahlback, B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. *Journal of Internal Medicine.* 2005, 257:209-233.

Christiansen SC, Cannegieter SC, Koster T, Vanderbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. *JAMA* 2005, 293:2352-61.

Mannucci, PM. Treatment of von Willebrand's Disease. *N Engl J Med.* 2004, 352:683-94.

Moake JL. Thrombotic microangiopathies. *NEJM* 2002, 347:589-600

Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. *Thrombosis Research* 2003, 108:3-13.

### **Myelodysplastic syndromes**

List A, Kurtin S, Roe DJ et al, Efficacy of Lenalidomide in myelodysplastic syndromes. NEJM 2005, 352:549-557

Cazzola, M and Malcovati L. Myelodysplastic syndromes – coping with ineffective hematopoiesis. NEJM 2005, 352: 536-538.

List A, et al, Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. NEJM 2006 355:1456-1465

### **Iron**

Pietrangelo A. Hereditary Hemochromatosis – a new look at an old disease. NEJM 2004, 350:2383-2397.

Nemeth E, Rivera S, Gabayan V et al, IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of iron regulatory hormone hepcidin. J. Clin. Invest. 2004, 113:1271-1276

Roy CN and Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005, 12:107-111.

### **Malaria**

Greenwood BM, Bojang K, Whitty CJM, Targett GAT. Malaria. Lancet 2005 365:1487-1498.

### **Large Granular Lymphocyte leukemia (LGL)**

Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. The Oncologist 2004, 9:247-258.

### **Autoimmune hemolytic anemia**

Cunningham MJ and Silberstein. Autoimmune hemolytic anemia. In Hematology: Basic Principles and Practice, Fourth Edition. (Hoffman, R., Ed.). Elsevier Science, Philadelphia, PA. 41: 693-707, 2005.

Moyo, V.M., Smith, B.D., Brodsky, I., Crilley, P., Jones, R.J., Brodsky, R.A. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood, 100:704-706, 2002.

### **Platelets**

Kickler KS, Oguni S, Borowitz MJ. A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia. Am J Clin Pathol 2006; 125:282-287.

Von Drygalski A, et al., Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007 Mar 1;356(9):904-10.

Warkentin TE. Drug-induced immune-mediated thrombocytopenia – from purpura to thrombosis. NEJM 2007, 356:891-893.

### **Consultative hematology**

Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. *Seminars in liver disease* 2002; 22: 83-96.

Caldwell SH et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. *Hepatology* 2006; 44:1039-46.

Strauss R et al. Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. *Critical Care Medicine* 2002; 30:1765-71.

McCrae KR, Samuels P, Schreiber AD. Pregnancy-associated thrombocytopenia: Pathogenesis and treatment. *Blood* 1992; 80:2697-2714.

Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. *British Journal of Haematology* 2006; 133:259-269.